Chennai, India — Authorities have apprehended the owner of a pharmaceutical firm following the tragic deaths of at least 21 children allegedly linked to a contaminated cough syrup produced at his facility. The young victims, all under the age of five, succumbed over the past month in Madhya Pradesh after being prescribed the syrup, raising serious health concerns.
G. Ranganathan, age 75, was arrested early Thursday at his residence in Chennai by combined forces from local police and officials from Madhya Pradesh. He faces serious charges, including culpable homicide not amounting to murder and drug adulteration, according to police sources and local media.
The cough syrup in question, branded as Coldrif, was manufactured by Sresan Pharma, located in Tamil Nadu. The Indian health ministry revealed that tests on samples identified contamination with diethylene glycol (DEG), a toxic chemical commonly used in industrial applications. Even minor ingestion of this substance can be lethal. In light of the recent events, Madhya Pradesh and several other states have instituted bans on the product.
This incident revives global scrutiny toward the Indian pharmaceutical sector, which has faced increased criticism in recent years. Cases have emerged in various countries where contaminated Indian-made medications resulted in fatalities. A spokesperson for the World Health Organization reportedly requested information from Indian officials to ascertain whether the tainted cough syrup was exported beyond the country’s borders.
The troubling trend of contaminated cough syrups is not isolated. In 2022, over 70 children in Gambia died from acute kidney failure caused by ingesting a syrup imported from India. Additionally, 68 children in Uzbekistan lost their lives between 2022 and 2023 due to another harmful syrup produced in India. These incidents prompted the U.S. Food and Drug Administration to collaborate with international bodies, including the World Health Organization, in early 2023 to investigate the growing concern over unsafe pharmaceutical products.
The Indian pharmaceutical industry, recognized as the third-largest globally by volume, has built a reputation for supplying medications worldwide. However, these recent tragedies challenge that standing and highlight the pressing need for enhanced regulatory oversight. Families affected by these losses continue to demand accountability and better safety measures in drug manufacturing.
As investigations unfold, this troubling episode raises critical questions about quality control in pharmaceuticals and the implications for public health, both nationally and internationally.